Observational studyThe Journal of antimicrobial chemotherapy2026
Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.
Observational study in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND AND
objectivesCYP2C19 phenotype is a known contributor to the interpatient variability in voriconazole response. Alternative therapy is recommended for ultrarapid/rapid and poor metabolizers due to increased probability of subtherapeutic exposure and side effects, respectively. We aimed to evaluate whether CYP2C19 phenotype is associated with switching from voriconazole to alternative antifungal therapy, in settings where genetic results were not available at the time prescribing decisions were made.
methodsA multicentre, retrospective observational study was conducted in three Australian hospitals. Patients who had previously taken voriconazole (from 1 May 2019 to 31 May 2024) were invited to undergo pharmacogenomic testing. Medical records were audited to compare switching decisions across patients with different CYP2C19 phenotypes. Differences in voriconazole exposure and voriconazole-related adverse effects were also explored.
resultsAmong 194 patients, most were normal or intermediate metabolizers (69%); 21% were rapid, 7% ultrarapid, and 3% poor metabolizers (underpowered). Switching to alternative antifungal therapy (32%; 62/194) mainly occurred due to adverse effect incidence and was not associated with CYP2C19 phenotype (P = 0.9041). C-reactive protein levels were significantly higher in patients who switched therapy (P < 0.001). All ultrarapid metabolizers on standard voriconazole 400 mg/day had subtherapeutic concentrations and only those on higher doses (500-1200 mg/day) achieved therapeutic concentrations.
conclusionsCYP2C19 phenotype was not predictive of switching, which is a multifactorial prescribing decision likely influenced by therapeutic drug monitoring, inflammation and clinical status. Our observations on voriconazole dosing and exposure support a complementary prescribing approach: pharmacogenomic testing to identify patients who require atypical voriconazole dosing regimens and subsequent therapeutic drug monitoring to guide dose adjustments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.